PDK4の多次元解析：がんバイオマーカーおよび免疫療法標的としての可能性
Yaxing Deng1, Xin Wang2, Mei Zeng1
1Department of Emergency Medicine, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Jiangyang District, Luzhou, 646000, Sichuan, China.
Purpose:
To explore the clinical significance of pyruvate dehydrogenase kinase 4 (PDK4) in pan-cancer and its potential as a tumor biomarker and immunotherapy target.
Methods:
Public databases (HPA, TCGA, GTEx, etc.) were used to analyze PDK4 expression, diagnostic efficacy, prognostic value, immune characteristics, genetic alterations, and immunotherapy responsiveness in pan-cancer. Targeted drugs were predicted via molecular docking.
Results:
PDK4 is predominantly expressed in skeletal muscle and specific cell types (basal prostatic cells, skeletal myocytes, etc.) in normal tissues. In most tumors, PDK4 expression is downregulated, with high diagnostic efficacy (AUC > 0.7 for most cancers) and independent prognostic value for overall survival (OS) in multiple tumors. PDK4 is enriched in immune cells (monocytes, myeloid DC) and positively correlated with immune infiltration and checkpoint genes. High PDK4 expression improves progression-free survival (PFS) in anti-PD-L1-treated patients, and tretinoin binds stably to PDK4.
Conclusions:
PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.
関連する概念動画
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway